Search results for "From ACP Journal Club"
Review compares effectiveness, cost, and safety of second-line drugs for diabetes
The review found that sulfonylureas were more cost-effective than newer agents, but an ACP Journal Club commentary stressed the importance of shared decision making in the choice of a second agent.
https://diabetes.acponline.org/archives/2018/02/09/6.htm
9 Feb 2018
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk
An ACP Journal Club commentary noted that the mechanism by which liraglutide improves renal outcomes is uncertain and that renal benefit was driven by a decrease in the surrogate outcome of macroalbuminuria, with measures of renal impairment remaining unchanged.
https://diabetes.acponline.org/archives/2018/01/12/9.htm
12 Jan 2018
Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes
While exenatide can be considered a second-line option for patients with type 2 diabetes and some may prefer its once-weekly dosing, those at high cardiovascular risk should receive agents with demonstrated cardiovascular benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/01/12/10.htm
12 Jan 2018
Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death
The review suggests that treating diabetes with strict glycemic control does not reduce mortality or cardiovascular risk or slow progression of kidney disease, and the results question whether strict glycemic control for preventing any complications is warranted, ACP Journal Club authors wrote.
https://diabetes.acponline.org/archives/2017/11/10/8.htm
10 Nov 2017
Self-monitoring of blood glucose did not improve HbA1c or QOL at 1 year in non-insulin-treated type 2 diabetes
The randomized controlled trial adds to the evidence about routine use of self-monitoring of blood glucose for all patients with type 2 diabetes, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/11/10/7.htm
10 Nov 2017
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years
The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching to pump therapy for glycemic control, hypoglycemia rates, or quality of life, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/09/08/6.htm
8 Sep 2017
Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
A commentary called for the findings to be confirmed with randomized controlled trials designed specifically to evaluate the effect of SGLT2 inhibitors on the kidneys.
https://diabetes.acponline.org/archives/2017/08/11/6.htm
11 Aug 2017
Bariatric surgery improved HbA1c at 5 y more than intensive medical care alone in obese patients with T2DM
A commentary considers the industry-funded STAMPEDE trial, in which obese patients with type 2 diabetes were randomly assigned to intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.
https://diabetes.acponline.org/archives/2017/06/09/6.htm
9 Jun 2017
Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics
A review looked at randomized trials that compared mortality rates among patients taking sulfonylureas versus several other classes of hypoglycemic drugs.
https://diabetes.acponline.org/archives/2017/05/12/6.htm
12 May 2017
Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF
The included studies focused on metformin use in patients with chronic kidney disease (CKD), congestive heart failure (CHF), chronic liver disease (CLD), or older age.
https://diabetes.acponline.org/archives/2017/05/12/7.htm
12 May 2017